STOCK TITAN
  1. Home
  2. Sec-filings
  3. IBRX
  4. [Form 4] ImmunityBio, Inc. Insider Trading Activity

ImmunityBio (IBRX) director sells 159,478 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ImmunityBio director Christobel Selecky exercised stock options and sold the resulting shares. She exercised options covering 124,414 shares at $2.99 per share and 35,064 shares at $2.98 per share, then sold 159,478 shares of Common Stock in open-market transactions at a weighted average price of $9.0236 per share, within a range of $9.00 to $9.07. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. After these transactions, the filing shows she holds no remaining common shares or related options.

Positive

  • None.

Negative

  • None.
Insider Selecky Christobel
Role null
Sold 159,478 shs ($1.44M)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 35,064 $0.00 --
Exercise Stock Option (right to buy) 124,414 $0.00 --
Exercise Common Stock 35,064 $2.98 $104K
Exercise Common Stock 124,414 $2.99 $372K
Sale Common Stock 159,478 $9.0236 $1.44M
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 35,064 shares (Direct, null)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Shares sold 159,478 shares Common Stock sold in open-market transactions
Weighted average sale price $9.0236 per share Sales in the $9.00–$9.07 price range
Option exercise size 1 124,414 shares Options exercised at $2.99 per share
Option exercise price 1 $2.99 per share Stock option (right to buy) conversion
Option exercise size 2 35,064 shares Options exercised at $2.98 per share
Option exercise price 2 $2.98 per share Stock option (right to buy) conversion
Net share change -159,478 shares Net-sell direction from transaction summary
Post-transaction holdings 0 shares Total common stock directly owned after transactions
Rule 10b5-1 trading plan regulatory
"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average share price financial
"Represents the weighted average share price of an aggregate total of 159,478 shares sold"
Stock Option (right to buy financial
"Stock Option (right to buy) ... underlying security title "Common Stock""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did ImmunityBio (IBRX) director Christobel Selecky do in this Form 4?
Director Christobel Selecky exercised stock options and sold the resulting shares. She converted options into 159,478 ImmunityBio common shares, then sold all of them in open-market trades, leaving no common stock holdings reported in this filing.

How many ImmunityBio (IBRX) shares were sold and at what price?
Selecky sold 159,478 ImmunityBio common shares. The weighted average sale price was $9.0236 per share, with individual trades executed in a price range between $9.00 and $9.07, according to the Form 4 footnote disclosure.

What option exercises are reported for ImmunityBio (IBRX) director Selecky?
She exercised options for 124,414 shares at a $2.99 exercise price and 35,064 shares at a $2.98 exercise price. These exercises converted her derivative positions into a total of 159,478 ImmunityBio common shares before the subsequent sales.

Was the ImmunityBio (IBRX) share sale made under a Rule 10b5-1 plan?
Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted by Selecky on March 13, 2026. Such plans pre-schedule trades, indicating the timing was set in advance rather than chosen opportunistically.

Does Christobel Selecky still hold ImmunityBio (IBRX) shares after these transactions?
Based on this Form 4, Selecky reports owning zero ImmunityBio common shares directly after the transactions. The derivative entries also show zero remaining option shares, indicating the reported options were fully exercised in connection with these trades.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Selecky Christobel
(Last)(First)(Middle)
C/O IMMUNITYBIO, INC.
3530 JOHN HOPKINS COURT
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M35,064A$2.9835,064D
Common Stock07/01/2026M124,414A$2.99159,478D
Common Stock07/01/2026S(1)159,478D$9.0236(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.9807/01/2026M35,06406/12/202306/14/2032Common Stock35,064$00D
Stock Option (right to buy)$2.9907/01/2026M124,41406/10/202406/13/2033Common Stock124,414$00D
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
2. Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Remarks:
/s/ Philip LoScalzo, as Attorney-in-Fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR